{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:02:38Z","timestamp":1785556958779,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.jneuroim.2007.07.022","type":"journal-article","created":{"date-parts":[[2007,9,8]],"date-time":"2007-09-08T07:19:33Z","timestamp":1189235973000},"page":"146-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The IgG subclass-specificities of anti-IFN\u03b2 antibodies change with time and differ between the IFN\u03b2 products in relapsing remitting multiple sclerosis patients"],"prefix":"10.1016","volume":"190","author":[{"given":"Ebrima","family":"Gibbs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Oger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2007.07.022_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2006.04.024","article-title":"During 3\u00a0years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4","volume":"177","author":"Basile","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1212\/01.WNL.0000046662.03894.C5","article-title":"Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients","volume":"60","author":"Bertolotto","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1084\/jem.179.2.757","article-title":"Human interleukin 10 induces naive surface immunoglobulin D+(sIgD+) B cells to secrete IgG1 and IgG3","volume":"179","author":"Briere","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.52.6.1239","article-title":"Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies","volume":"52","author":"Deisenhammer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/107999001750133195","article-title":"Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b","volume":"21","author":"Deisenhammer","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib6","first-page":"11","article-title":"A novel assay to detect low-titred antibodies to interferon beta in multiple sclerosis patients","volume":"29","author":"Di Marco","year":"2006","journal-title":"New Microbiol."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib7","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00006454-199008001-00004","article-title":"IgG subclass distribution of antibodies to bacterial and viral antigens","volume":"9","author":"Ferrante","year":"1990","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1212\/01.wnl.0000171748.48188.5b","article-title":"Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS","volume":"65","author":"Francis","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib9","first-page":"473","article-title":"Serum IgG subclass concentrations in healthy adults: a study using monoclonal antisera","volume":"56","author":"French","year":"1984","journal-title":"Clin. Exp. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.jneuroim.2007.07.022_bib10","first-page":"S162","article-title":"Patterns of anti-interferon beta antibody formation at the University of British Columbia MS Clinics","volume":"11","author":"Gibbs","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib11","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/clinchem\/33.10.1707","article-title":"Human IgG subclass measurements in the clinical laboratory","volume":"33","author":"Hamilton","year":"1987","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0022-1759(93)90263-7","article-title":"Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies","volume":"158","author":"Hamilton","year":"1993","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/01.wnl.0000171747.59767.5c","article-title":"Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study","volume":"65","author":"Kappos","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1365-2567.1996.d01-634.x","article-title":"Role of interleukin-2 and interferon-gamma in inducing production of IgG subclasses in lymphocytes of human newborns","volume":"88","author":"Kawano","year":"1996","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib15","first-page":"17","article-title":"MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity","volume":"7","author":"Pachner","year":"2003","journal-title":"Mol. Diagn."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/10408368909106589","article-title":"Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects","volume":"27","author":"Papadea","year":"1989","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib16","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/clinchem\/31.12.1940","article-title":"Monoclonal antibody-based solid-phase immunoenzymometric assays for quantifying human immunoglobulin G and its subclasses in serum","volume":"31","author":"Papadea","year":"1985","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/hyb.1984.3.263","article-title":"Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes","volume":"3","author":"Reimer","year":"1984","journal-title":"Hybridoma"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib19","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1212\/WNL.50.5.1266","article-title":"Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"50","author":"Rudick","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1056\/NEJM198007243030402","article-title":"Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens","volume":"303","author":"Siber","year":"1980","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2007.07.022_bib21","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(03)14541-2","article-title":"Clinical importance of neutralising antibodies against interferon beta in patients with relapsing\u2013remitting multiple sclerosis","volume":"362","author":"Sorensen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib22","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1212\/01.wnl.0000242884.76598.bb","article-title":"Neutralizing antibodies hamper IFN\u03b2eta bioactivity and treatment effect on MRI in patients with MS","volume":"67","author":"Sorensen","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1212\/WNL.47.4.889","article-title":"Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years","volume":"47","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib24","first-page":"1628","article-title":"PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. [see comment][erratum appears in Neurology 2001 Sep 25;57(6):1146]","volume":"56","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2007.07.022_bib25","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1212\/WNL.58.12.1786","article-title":"Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients","volume":"58","author":"Vallittu","year":"2002","journal-title":"Neurology"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572807002652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572807002652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:07:31Z","timestamp":1759046851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572807002652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":25,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0165572807002652"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2007.07.022","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The IgG subclass-specificities of anti-IFN\u03b2 antibodies change with time and differ between the IFN\u03b2 products in relapsing remitting multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2007.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}